BCIQ Profiles

Company Profile Report
0607 Accelerated Neurodegenerative
BioCentury & Getty Images

Product Development

Aducanumab approval sets precedent for accelerated approval for neurodegenerative diseases

FDA’s approval of Biogen Alzheimer’s therapy paves way for other neurodegenerative disease drugs

FDA’s accelerated approval of Biogen’s aducanumab to treat Alzheimer’s disease paves way for approvals based on surrogate endpoints of other neurodegenerative disease therapies.

Jun 7, 2021 | 9:43 PM GMT

FDA’s accelerated approval of Biogen’s aducanumab to treat Alzheimer’s creates a path for approvals based on surrogate endpoints of other neurodegenerative disease therapies. It isn’t clear, however, if FDA will require more scientific

Read the full 892 word article

How to gain access

Continue reading with a
two-week free trial.